Using Facebook to help young adults quit smoking

May 24, 2018 - 10:11am

By Elizabeth Fernandez [1]
Participants assigned to the Tobacco Status Project were two and a half times more likely to have biochemically verified abstinence from smoking at three months compared to those in study control groups.

A national clinical trial testing a smoking cessation intervention for young adults that was conducted entirely on Facebook has found that smokers are 2.5 times more likely to quit after three months with the Facebook-based treatment than if they were referred to an online quit-smoking program.

It is the first study to test the effectiveness of a smoking intervention delivered entirely on Facebook and to also use biochemically-verified abstinence from smoking.

Quit rates were the same between the two groups after a year. Researchers said they believe the method is promising, and can be used effectively to support short-term positive behavior change, especially among young adult smokers, which has been a challenging group to reach and treat.

The study was published May 24, 2018 [2] in the journal *Addiction*.

**Novel UCSF project finds social media treatment can be effective even for those not ready to quit**

“We were doing something very ambitious by taking those who were not necessarily ready to stop smoking and seeing if this form of intervention could help,” said first and corresponding author Danielle Ramo, PhD [3], an associate professor of psychiatry at UCSF and member of the **UCSF Weill Institute for Neurosciences** [4].

“We found that we could reach a hard-to-reach population, have short-term abstinence, and also have excellent engagement,” Ramo said. “It suggests that the social media environment can be an engaging tobacco treatment tool, even for those not ready to quit. This group may have participated in the trial solely for monetary incentives, but their engagement and limited dropout suggest that a social media intervention could help them move toward long-term abstinence.”
Young adulthood has been widely demonstrated to be when people are most likely to smoke. In the United States, studies show that almost all smokers reported starting before the age of 26. While young adults are as motivated to quit as older smokers, they are less likely to use evidence-based treatments for smoking cessation, such as medication, counseling, or phone-based quit lines, research has shown. As a result, social media-based programs could potentially expand the reach of cessation services.

For the study, the researchers created the Tobacco Status Project, a 90-day motivational program in which participants were assigned to secret (private) Facebook groups tailored to their readiness to quit smoking. The intervention consisted of methods including daily posts, weekly live question and answer sessions, and weekly live cognitive behavioral counseling sessions with a doctoral-level smoking cessation counselor. The control group received a referral to the National Cancer Institute’s Smokefree.gov website and was encouraged to actively use it for the duration of the trial.

The study sample was similar to the U.S. population of smokers. Altogether, 500 people participated: 45 percent were males, 73 percent were white and 87 percent were daily smokers. The mean age was nearly 21. Participants did not have to want to quit smoking to be involved in the study.

The authors assessed abstinence at the beginning, then at three months, six months and 12 months. Participants could receive a monetary incentive consisting of gift cards at each assessment, plus a $20 bonus for completing all three, for a total possible incentive of $100.

Researchers found that the social media program had a significant effect on quitting during the time that the intervention was active, amounting to three months, although that effect was not sustained at a year during follow-up assessments. As expected, the researchers also found that abstinence over a longer period occurred among those who were prepared to stop smoking versus those who simply contemplated it or those who were not thinking about it at all.

Those assigned to the Tobacco Status Project were two and a half times more likely to have biochemically verified abstinence from smoking compared to controls at three months (8.3 percent vs. 3.2 percent). Over 12 months, that difference was no longer significant.

The researchers did not provide nicotine replacement, nor did study participants report using it. The authors noted that nicotine replacement along with online treatment may help to improve quit rates in future studies.

"Digital interventions can sometimes suffer from low engagement," said Ramo. "We saw high engagement overall, with more than three-fourths of those in the project commenting at least once during the intervention, and the average person commented 31 times. We also saw a significant difference at the end of treatment. This is exciting. It was highly engaging for the participants. This is a form of intervention that really appeals to young people."

Ramo’s research focuses on using digital media to address tobacco, drug and alcohol use. She directs the UCSF Research on Addiction and Digital Interventions Lab and co-directs the Digital Health Core in the Department of Psychiatry. She is also a member of the UCSF Helen Diller Family Comprehensive Cancer Center.
Funding was provided by a career development award from the National Institute on Drug Abuse (K23DA032578).

Co-authors are Johannes Thrul, PhD, an assistant professor at the Johns Hopkins Bloomberg School of Public Health; Kevin L. Delucchi, PhD, a UCSF professor of psychiatry; Sharon Hall, PhD, a UCSF professor emeritus of psychiatry; Pamela M. Ling, MD, a UCSF professor of medicine; Alina Belohlavek, a clinical research coordinator in the UCSF Department of Psychiatry; and senior author Judith J. Prochaska, PhD, MPH, an associate professor of medicine at Stanford University.

Ramo has consulted to Carrot, Inc., which makes a tobacco cessation device. Hall has consulted to Carrot and Biorealm. Prochaska has consulted to Pfizer, which makes smoking medications, is an advisor to Carrot, and has been an expert witness for plaintiffs’ counsel in court cases against tobacco companies.

Read the study

- Addiction: A randomized controlled evaluation of the Tobacco Status Project, a Facebook intervention for young adults

Further coverage

- San Francisco Chronicle: Can Facebook help you quit smoking? Study says yes

About UCSF Psychiatry

The UCSF Department of Psychiatry and the Langley Porter Psychiatric Institute are among the nation’s foremost resources in the fields of child, adolescent, adult, and geriatric mental health. Together they constitute one of the largest departments in the UCSF School of Medicine and the UCSF Weill Institute for Neurosciences, with a mission focused on research (basic, translational, clinical), teaching, patient care and public service.

UCSF Psychiatry conducts its clinical, educational and research efforts at a variety of locations in Northern California, including UCSF campuses at Parnassus Heights, Mission Bay and Laurel Heights, UCSF Medical Center, UCSF Benioff Children's Hospitals, Zuckerberg San Francisco General Hospital and Trauma Center, the San Francisco VA Health Care System and UCSF Fresno.

About the UCSF Weill Institute for Neurosciences

The UCSF Weill Institute for Neurosciences, established by the extraordinary generosity of Joan and Sanford I. "Sandy" Weill, brings together world-class researchers with top-ranked physicians to solve some of the most complex challenges in the human brain.

The UCSF Weill Institute leverages UCSF’s unrivaled bench-to-bedside excellence in the neurosciences. It unites three UCSF departments?Neurology, Psychiatry, and Neurological Surgery?that are highly esteemed for both patient care and research, as well as the
Neuroscience Graduate Program, a cross-disciplinary alliance of nearly 100 UCSF faculty members from 15 basic-science departments, as well as the UCSF Institute for Neurodegenerative Diseases, a multidisciplinary research center focused on finding effective treatments for Alzheimer’s disease, frontotemporal dementia, Parkinson’s disease, and other neurodegenerative disorders.

About UCSF

UC San Francisco (UCSF) is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. It includes top-ranked graduate schools of dentistry, medicine, nursing and pharmacy; a graduate division with nationally renowned programs in basic, biomedical, translational and population sciences; and a preeminent biomedical research enterprise. It also includes UCSF Health, which comprises top-ranked hospitals – UCSF Medical Center and UCSF Benioff Children’s Hospitals in San Francisco and Oakland – and other partner and affiliated hospitals and healthcare providers throughout the Bay Area.

Contact Us
Psychiatry Intranet
UCSF Webmail
UCSF Main Site

© 2018 The Regents of the University of California
